Moderate, Deep Sedation
Conditions
Keywords
Procedural sedation, ketamine, children
Brief summary
There is a wide variation of published IV ketamine dosing regimens used for procedural sedation in children in the Emergency Department (ED). The purpose of the study was to compare the efficacy, duration of sedation and adverse events between the three commonly administered doses of IV ketamine (1 mg/kg, 1.5 mg/kg and 2 mg/kg) using the traditional administration method of 30-60 second infusion for ED sedation in children.
Detailed description
This was a prospective, double-blind, randomized controlled trial of children aged 3 to 18 years who received IV ketamine for procedural sedation and analgesia (PSA) for orthopedic procedures, incision and drainage (I & D) of skin abscess and laceration repair in an inner city, tertiary care pediatric ED. Random sequence allocation was performed using a computer-generated, random number table by the study research pharmacist. The study participants were grouped according to their age as follows (1) 3-6 years (2) 7-12 years (3) 13-18 years. Children from each age group were assigned in equal numbers to all three ketamine dosing (1 mg/kg, 1.5 mg/kg and 2 mg/kg) groups using random permuted blocks stratified by the pharmacist. All ED staff including the physician and the nurse in charge of sedation, the study research assistant, the parents/guardians and the study subjects were blinded to the randomization and the group assignments. The dosage and administration of additional doses of ketamine were left to the discretion of the ED physician in charge of the sedation. The research team did not participate in the clinical care including sedation of the patient. Children were monitored per ED policy for the entire duration of sedation. Three 1 ml blood samples for the ketamine assay was collected from the existing intravenous access at three time intervals: 3-5 minutes after ketamine administration, at midpoint during the procedure and prior to discharge of the patient from the ED. In the event a second dose of ketamine was administered, a 4th 1 ml sample was collected 3-5 minutes after the 2nd dose in children weighing \>20 kilograms. Patient demographics, procedure type, NPO status , ASA classification, pain medication administered prior to sedation (timing, dosage and type), number and total doses of ketamine administered after the initial study dose, sedation efficacy and duration, length of procedure, adverse events related to sedation, interventions performed to address the adverse events and patient disposition were collected. The study research assistant also performed a follow up phone call to the parents/caregivers of the children 48 hours after ED discharge to collect information on adverse events that happened at home . A total of 3 attempts were made to contact the parent/caregiver after which the participant was considered as lost to followup.
Interventions
Intervention: Ketamine IV 1mg/kg
Intervention: Ketamine IV 1.5 mg/kg
Intervention: Ketamine IV 2 mg/kg
Sponsors
Study design
Eligibility
Inclusion criteria
* Children 3 -18 years of age * Belonging to American Society of Anesthesiologists (ASA) classification 1 or 2 * Receiving IV ketamine for procedural sedation for orthopedic procedures, * Incision and Drainage of skin abscess and laceration repair
Exclusion criteria
* Contraindications to use of Ketamine * Parents or legal guardian not available or declined to provide informed consent * Child declined to provide assent, * Patients that received intramuscular ketamine, * Patient that received benzodiazepines in addition to ketamine * Children weighing \>100 kilogram * Children with developmental disabilities.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sedation Efficacy | Participants will be assessed after study drug adminsitration and the maximum depth of sedation achieved recorded. Approximately 2 hours | Measure sedation depth using Ramsay Sedation Scale. Varies from 1-6 with 1: anxious, agitated, restless 2: Cooperative, oriented, tranquil 3: responsive to commands 4: Brisk response to light glabellar tap or auditory stimulus 5: Sluggish response to light glabellar tap or loud auditory stimulus 6 being no response to light glabellar tap or loud auditory stimulus. Higher the score, greater is the depth of sedation. Use of ketamine usually provides a depth of sedation of 5 or 6. |
| Pain | Patients will be assessed during the procedure after administration of sedation medicaiton. Approximately 30 minutes | Measure pain using self reported Wong Baker faces pain rating scale prior to sedation, during sedation and prior to discharge.The scale shows a series of faces ranging from a happy face at 0, No hurt to a crying face at 10 Hurts worst. The patient must choose the face that best describes how they are feeling. The score has values of 0(no hurt), 2(hurts little bit), 4(hurts little more), 6(hurts even more), 8(hurts whole lot),10 (hurts worst). The patient chooses one number that describes the pain best (eg. Either a 2 or 4). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sedation Duration | Patients will be assessed during the length of time from administration of sedation medication until ready for discharge, Approximately 3 hours | Length of sedation was defined as the time duration from the administration of study medication until ready for discharge using standardized discharge criteria (Aldrete scoring \>9) followed at our institution. |
| Additional Dose | Patients will be assessed during procedure . Approximately 1 hours | Number of participants to whom additional doses of ketamine administered apart from the study dose |
| Adverse Events | Patients will be assessed after administration of medication until discharge and will have a follow up phone call 48 hours after discharge for 3 attempts. 5 days., | Adverse events secondary to sedation experienced by the patient and interventions performed to overcome them |
| Sedation Satisfaction | At the end of the procedure. Approximately 1 hour | Consultants will be asked to rate their level of satisfaction with sedation on a Likert Scale of 1-3 |
Participant flow
Recruitment details
Conducted at a level 1 trauma Pediatric Emergency Department from July 1st 2010 to August 31st 2012. We enrolled a convenience sample of eligible patients. Study participants were identified using the electronic medical tracking board which lists the presenting complaint and after need for IV ketamine sedation was established with physician.
Pre-assignment details
11 consented patients were excluded as sedation and procedure was performed in the operating room rather than in the Emergency Department
Participants by arm
| Arm | Count |
|---|---|
| Ketamine IV 1 mg/kg Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
Ketamine IV 1mg/kg: Intervention: Ketamine IV 1mg/kg | 50 |
| Ketamine IV 1.5 mg/kg Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
Ketamine IV 1.5mg/kg: Intervention: Ketamine IV 1.5 mg/kg | 35 |
| Ketamine IV 2 mg/kg Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
Ketamine IV 2mg/kg: Intervention: Ketamine IV 2 mg/kg | 40 |
| Total | 125 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Protocol Violation | 8 | 22 | 16 |
Baseline characteristics
| Characteristic | Total | Ketamine IV 2 mg/kg | Ketamine IV 1.5 mg/kg | Ketamine IV 1 mg/kg |
|---|---|---|---|---|
| Age, Customized 13-18 years | 16 participants | 6 participants | 4 participants | 6 participants |
| Age, Customized 3-6 years | 56 participants | 16 participants | 18 participants | 22 participants |
| Age, Customized 7-12 years | 53 participants | 18 participants | 13 participants | 22 participants |
| AMerican Society of Anesthesiologists (ASA) Category ASA Class 1, A normal healthy patient | 119 participants | 37 participants | 32 participants | 50 participants |
| AMerican Society of Anesthesiologists (ASA) Category ASA class 2, Mild systemic disease | 5 participants | 3 participants | 2 participants | 0 participants |
| AMerican Society of Anesthesiologists (ASA) Category ASA class 3, Severe systemic disease | 1 participants | 0 participants | 1 participants | 0 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 14 Participants | 6 Participants | 1 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 102 Participants | 32 Participants | 31 Participants | 39 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 9 Participants | 2 Participants | 3 Participants | 4 Participants |
| Procedure Type Fracture/Dislocation Reduction | 89 participants | 35 participants | 21 participants | 33 participants |
| Procedure Type Incision and Drainage | 25 participants | 2 participants | 11 participants | 12 participants |
| Procedure Type Laceration Repair | 11 participants | 3 participants | 3 participants | 5 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 66 Participants | 18 Participants | 27 Participants | 21 Participants |
| Race (NIH/OMB) More than one race | 5 Participants | 1 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 18 Participants | 9 Participants | 3 Participants | 6 Participants |
| Race (NIH/OMB) White | 32 Participants | 11 Participants | 5 Participants | 16 Participants |
| Sex: Female, Male Female | 54 Participants | 13 Participants | 18 Participants | 23 Participants |
| Sex: Female, Male Male | 71 Participants | 27 Participants | 17 Participants | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 5 / 50 | 5 / 35 | 4 / 40 |
| serious Total, serious adverse events | 0 / 50 | 0 / 35 | 0 / 40 |
Outcome results
Pain
Measure pain using self reported Wong Baker faces pain rating scale prior to sedation, during sedation and prior to discharge.The scale shows a series of faces ranging from a happy face at 0, No hurt to a crying face at 10 Hurts worst. The patient must choose the face that best describes how they are feeling. The score has values of 0(no hurt), 2(hurts little bit), 4(hurts little more), 6(hurts even more), 8(hurts whole lot),10 (hurts worst). The patient chooses one number that describes the pain best (eg. Either a 2 or 4).
Time frame: Patients will be assessed during the procedure after administration of sedation medicaiton. Approximately 30 minutes
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ketamine IV 1 mg/kg | Pain | 0 units on a scale |
| Ketamine IV 1.5 mg/kg | Pain | 0 units on a scale |
| Ketamine IV 2 mg/kg | Pain | 0 units on a scale |
Sedation Efficacy
Measure sedation depth using Ramsay Sedation Scale. Varies from 1-6 with 1: anxious, agitated, restless 2: Cooperative, oriented, tranquil 3: responsive to commands 4: Brisk response to light glabellar tap or auditory stimulus 5: Sluggish response to light glabellar tap or loud auditory stimulus 6 being no response to light glabellar tap or loud auditory stimulus. Higher the score, greater is the depth of sedation. Use of ketamine usually provides a depth of sedation of 5 or 6.
Time frame: Participants will be assessed after study drug adminsitration and the maximum depth of sedation achieved recorded. Approximately 2 hours
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ketamine IV 1 mg/kg | Sedation Efficacy | 5.5 units on a scale |
| Ketamine IV 1.5 mg/kg | Sedation Efficacy | 6 units on a scale |
| Ketamine IV 2 mg/kg | Sedation Efficacy | 6 units on a scale |
Additional Dose
Number of participants to whom additional doses of ketamine administered apart from the study dose
Time frame: Patients will be assessed during procedure . Approximately 1 hours
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ketamine IV 1 mg/kg | Additional Dose | 8 participants |
| Ketamine IV 1.5 mg/kg | Additional Dose | 1 participants |
| Ketamine IV 2 mg/kg | Additional Dose | 2 participants |
Adverse Events
Adverse events secondary to sedation experienced by the patient and interventions performed to overcome them
Time frame: Patients will be assessed after administration of medication until discharge and will have a follow up phone call 48 hours after discharge for 3 attempts. 5 days.,
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ketamine IV 1 mg/kg | Adverse Events | Adverse events in ED | 5 participants |
| Ketamine IV 1 mg/kg | Adverse Events | Post discharge Emesis | 4 participants |
| Ketamine IV 1.5 mg/kg | Adverse Events | Adverse events in ED | 5 participants |
| Ketamine IV 1.5 mg/kg | Adverse Events | Post discharge Emesis | 4 participants |
| Ketamine IV 2 mg/kg | Adverse Events | Adverse events in ED | 4 participants |
| Ketamine IV 2 mg/kg | Adverse Events | Post discharge Emesis | 6 participants |
Sedation Duration
Length of sedation was defined as the time duration from the administration of study medication until ready for discharge using standardized discharge criteria (Aldrete scoring \>9) followed at our institution.
Time frame: Patients will be assessed during the length of time from administration of sedation medication until ready for discharge, Approximately 3 hours
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ketamine IV 1 mg/kg | Sedation Duration | 23 Minutes |
| Ketamine IV 1.5 mg/kg | Sedation Duration | 24.5 Minutes |
| Ketamine IV 2 mg/kg | Sedation Duration | 23 Minutes |
Sedation Satisfaction
Consultants will be asked to rate their level of satisfaction with sedation on a Likert Scale of 1-3
Time frame: At the end of the procedure. Approximately 1 hour
Population: consultant satisfaction missing in 6 participants
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ketamine IV 1 mg/kg | Sedation Satisfaction | Very Satisfied | 27 participants |
| Ketamine IV 1 mg/kg | Sedation Satisfaction | Not satisfied | 10 participants |
| Ketamine IV 1 mg/kg | Sedation Satisfaction | Satisfied | 12 participants |
| Ketamine IV 1.5 mg/kg | Sedation Satisfaction | Very Satisfied | 29 participants |
| Ketamine IV 1.5 mg/kg | Sedation Satisfaction | Satisfied | 3 participants |
| Ketamine IV 1.5 mg/kg | Sedation Satisfaction | Not satisfied | 2 participants |
| Ketamine IV 2 mg/kg | Sedation Satisfaction | Very Satisfied | 29 participants |
| Ketamine IV 2 mg/kg | Sedation Satisfaction | Satisfied | 6 participants |
| Ketamine IV 2 mg/kg | Sedation Satisfaction | Not satisfied | 1 participants |